Trial Profile
A Phase IIa Study of Rintatolimod Plus Pembrolizumab in Refractory Metastatic Colorectal Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Rintatolimod (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 24 Jan 2022 Status changed from not yet recruiting to withdrawn prior to enrolment due to implementation issues.
- 04 Jan 2022 Planned End Date changed from 30 Nov 2024 to 1 Feb 2024.
- 04 Jan 2022 Planned primary completion date changed from 30 Nov 2023 to 1 Feb 2024.